How The Flu Vaccine Works And Why It Changes?

Every fall, millions of people roll up their sleeves for a flu shot. Many of them got one last year too, and the year before that. The reason it is not a one-and-done vaccine comes down to two things: how the virus changes, and how the vaccine is built to match it.

The flu vaccine works by teaching your immune system to recognize proteins on the surface of influenza viruses. It changes every year because those surface proteins mutate, and because the vaccine is reformulated annually to match the strains researchers expect to circulate. When the match is good, protection is better. When the virus drifts, protection drops.

That is the short version. The longer version involves a global surveillance network, a decision made months before flu season starts, and a manufacturing process that has to hit a moving target.

How The Flu Vaccine Works And Why It Changes?

The vaccine introduces your immune system to pieces of influenza virus — either killed virus, weakened virus, or just a few viral proteins. Your body responds by producing antibodies against those proteins. If you later encounter a real flu virus with the same proteins, those antibodies can recognize and attack it before it causes serious illness.

The two main proteins on the virus surface are hemagglutinin (H) and neuraminidase (N). These are the proteins your antibodies target. They are also the proteins that mutate most readily. That combination — important for immunity, prone to change — is why the vaccine has to be updated.

Influenza viruses change in two ways. The first is called antigenic drift: small, gradual mutations in H and N that accumulate over time. Drift is why seasonal flu vaccines need updating every year. The second is antigenic shift: a major genetic reassortment that can produce a virus with entirely new surface proteins. Shift is rare but is what can lead to a pandemic, because most people have little existing immunity to the new virus.

Seasonal vaccines are designed to address drift. They are not designed to predict or prevent a pandemic strain.

Why Does The Flu Vaccine Change Every Year?

The World Health Organization coordinates a global network of laboratories that collect and analyze influenza samples year-round. Twice a year — once for the Northern Hemisphere and once for the Southern Hemisphere — the WHO makes a recommendation about which strains to include in the coming season’s vaccine.

That recommendation comes months before flu season begins. Manufacturers then need several months to produce hundreds of millions of doses. This timing creates a fundamental problem: the strains chosen in February or March for the Northern Hemisphere may not be the strains circulating most widely by December.

Several things can happen between the recommendation and the season:

• The predicted strains circulate as expected, and the vaccine is a good match.
• A strain not included in the vaccine becomes dominant.
• An included strain mutates enough that antibodies from the vaccine recognize it less well.

When the match is good, the vaccine tends to work better. When it is not, effectiveness drops. This is not a failure of the vaccine — it is the inherent challenge of vaccinating against a virus that evolves faster than the manufacturing timeline.

What Strains Are In This Year’s Flu Vaccine?

Most seasonal flu vaccines protect against four influenza strains: two influenza A strains (typically H1N1 and H3N2) and two influenza B strains. This is called a quadrivalent vaccine. Some vaccines protect against three strains (trivalent), though quadrivalent formulations have become the standard in the US in recent years.

The specific strains included each year vary. They are selected based on surveillance data showing which viruses are circulating and how they are evolving. The WHO publishes its recommendations, and national regulatory agencies like the FDA make the final decision for their country.

Because the strains change, you cannot assume last year’s vaccine offers meaningful protection this year. Even if one or two strains overlap, the others may differ, and your antibody levels from last year’s shot have likely declined.

How Long Does Flu Vaccine Protection Last?

Antibody levels from the flu vaccine decline over months. Protection is generally strongest in the weeks right after vaccination and tends to wane over the course of a flu season. This is one reason public health agencies recommend getting vaccinated in early fall — late September or October for most people in the US — so that protection is still reasonably strong when flu activity typically peaks in winter.

Getting vaccinated too early in the season, such as in July or August, could mean your protection has faded somewhat by the time flu is most widespread. But getting it too late means you are unprotected during the early part of the season. The exact timing recommendation may vary by year and by individual circumstances, so checking current guidance from a healthcare provider or public health agency is reasonable.

There is also evidence that repeated annual vaccination may affect how well the vaccine works in some seasons, though the findings are mixed and the research is ongoing. Some studies suggest that prior vaccination can blunt the response to a new vaccine in certain situations. Other studies do not show this. The current consensus among public health agencies remains that annual vaccination is recommended, because the benefits of protection outweigh the uncertainty around this effect.

Why Do Some People Still Get The Flu After Vaccination?

No vaccine is 100 percent effective. Flu vaccine effectiveness varies by season and by the match between vaccine strains and circulating viruses. Even in a well-matched season, some vaccinated people will still get sick.

There are several reasons:

• Imperfect match: The circulating strain may have drifted from the vaccine strain.
• Individual immune response: Older adults and people with certain health conditions may mount a weaker response to vaccination.
• Other viruses: Many illnesses that feel like “the flu” are caused by other respiratory viruses, such as rhinovirus or RSV, which the flu vaccine does not target.
• Exposure timing: You can be exposed to flu before your immune system has fully responded to the vaccine, which takes about two weeks.

Even when the vaccine does not prevent illness entirely, there is evidence that it can reduce the severity of illness and the risk of complications in people who do get sick. The strength of that effect varies, and it is not a guarantee.

Who Should Get The Flu Vaccine?

Public health agencies in the US recommend annual flu vaccination for everyone aged 6 months and older, with rare exceptions. Certain groups are at higher risk of serious complications from flu, including adults 65 and older, young children, pregnant women, and people with chronic conditions like asthma, diabetes, or heart disease.

Different vaccine formulations are available for different age groups. Adults 65 and older are often recommended a higher-dose or adjuvanted vaccine, which is designed to produce a stronger immune response in older adults whose immune systems may respond less robustly to standard vaccines. The evidence for these formulations shows they can improve the immune response, though the clinical advantage over standard-dose vaccines varies.

People with severe allergies to vaccine components, or those who have had a severe reaction to a flu vaccine in the past, should talk to a healthcare provider before getting vaccinated. This is a small group, and the specific contraindications are well defined in clinical guidance.

How Are Flu Vaccines Made?

Most flu vaccines in the US are still produced using egg-based manufacturing, a method that has been used for decades. The selected virus strains are injected into fertilized chicken eggs, where they replicate. The virus is then harvested, inactivated or weakened, and purified.

There are also cell-based and recombinant flu vaccines. Cell-based vaccines are grown in mammalian cells rather than eggs. Recombinant vaccines use a different approach entirely — they use engineered cells to produce just the hemagglutinin protein, without growing actual influenza virus. These methods can sometimes be faster to scale and may avoid certain egg-related issues, though the goal is the same: produce a vaccine that teaches the immune system to recognize the target strains.

The manufacturing method can affect how well the vaccine works in certain populations, but the differences are generally modest and vary by season and strain.